The Eph family of receptor tyrosine kinases and their ligands, known as ephrins, play a crucial role in vascular development during embryogenesis. The function of these molecules in adult angiogenesis has not been well characterized. Here, we report that blocking Eph A class receptor activation inhibits angiogenesis in two independent tumor types, the RIP-Tag transgenic model of angiogenesis-dependent pancreatic islet cell carcinoma and the 4T1 model of metastatic mammary adenocarcinoma. Ephrin-A1 ligand was expressed in both tumor and endothelial cells, and EphA2 receptor was localized primarily in tumor-associated vascular endothelial cells. Soluble EphA2-Fc or EphA3-Fc receptors inhibited tumor angiogenesis in cutaneous window assays, and tumor growth in vivo. EphA2-Fc or EphA3-Fc treatment resulted in decreased tumor vascular density, tumor volume, and cell proliferation, but increased cell apoptosis. However, EphA2-Fc had no direct effect on tumor cell growth or apoptosis in culture, yet inhibited migration of endothelial cells in response to tumor cells, suggesting that the soluble receptor inhibited blood vessel recruitment by the tumor. These data provide the first functional evidence for Eph A class receptor regulation of pathogenic angiogenesis induced by tumors and support the function of A class Eph receptors in tumor progression.
Introduction
Angiogenesis, the process by which new blood vessels are formed from existing vasculature, has been shown to be a critical step in the progression and metastasis of solid tumors (Folkman, 1990 (Folkman, , 1994 Weidner, 1996) . Recruitment of new blood vessels by tumors enables tumor survival and growth via delivery of oxygen and host nutrients to the tumor, thus promoting malignant progression. Tumor vascular density has been correlated with malignant progression and a poor prognosis for patients suffering from breast and pancreatic carcinoma (Goede et al., 1998; Kuehn et al., 1999; Weidner et al., 1991 Weidner et al., , 1992 . Indeed, newly formed tumor vasculature often displays breaches in basement membrane integrity, which may permit invasion by tumor cells and thereby facilitate metastasis (Dankort and Muller, 1996; Weidner, 1996) . Therefore, understanding the molecular mechanisms that regulate tumor angiogenesis will enhance our understanding of tumor progression, and provide novel targets for therapeutic intervention in cancer.
Receptor tyrosine kinases (RTKs) have emerged as critical mediators of angiogenesis (reviewed in Cheng et al., 2002; Gale and Yancopoulos, 1999; Yancopoulos et al., 2000) . For example, the vascular endothelial growth factor (VEGF) family of ligands and their RTKs function in endothelial cell differentiation and blood vessel patterning during embryonic development, and are also required for tumor angiogenesis. The Eph family of RTKs and their ligands, known as ephrins, were originally identified as critical determinants of embryonic patterning and neuronal targeting (Holder and Klein, 1999) . These molecules also regulate embryonic vascular development (Gale and Yancopoulos, 1999; Yancopoulos et al., 2000) . Targeted disruption of, ephrinB2, EphB2/EphB3 or EphB4, results in embryonic lethality due to defects in primary capillary network remodeling and subsequent patterning defects in the embryonic vasculature (Adams et al., 1999a; Gerety et al., 1999; Wang et al., 1998b) , suggesting that Eph RTKs and their ligands are critical for vascular development during embryogenesis. The A class ligand, ephrin-A1, was originally identified as a TNF-a-inducible gene in human umbilical vein endothelial cells (HUVEC) (Holzman et al., 1990) , and is expressed in the developing vasculature during embryogenesis (McBride and Ruiz, 1998) . Moreover, ephrin-A1 induces endothelial cell migration and capillary assembly in vitro, and angiogenesis in the corneal pocket assay in vivo (Daniel et al., 1996; Myers et al., 2000; Pandey et al., 1995) . These studies indicate that Eph signaling is critical for normal blood vessel development, and suggest that these molecules may also play a role in angiogenesis caused by pathologic stages in the adult.
In this study, we report complementary expression of ephrin-A1 ligand in tumor cells and EphA2 receptor in tumor associated blood vessel endothelium. Soluble EphA-Fc receptors inhibited tumor angiogenesis in cutaneous window assays and tumor progression in vivo. Moreover, soluble Eph receptors inhibited tumorinduced endothelial cell migration in culture. These data provide the first evidence for A class Eph receptor signaling in tumor angiogenesis, and suggest that targeting these molecules may be an effective therapeutic strategy in cancer treatment.
Results

Ephrin-A1 and EphA2 are expressed in RIP-Tag tumors and associated vasculature
To determine if Eph A class receptors and ligands play a role in tumor angiogenesis, we first examined the expression and localization of ephrin-A1 and EphA2 proteins in vascularized tumor tissue. We focused on this ligand and receptor pair as previous studies have correlated ephrin-A1 and EphA2 overexpression in several types of human tumors (Ogawa et al., 2000) . The RIP-Tag transgenic model of multi-stage carcinogenesis, in which the rat insulin promoter drives expression of the SV40 large T antigen oncogene in pancreatic b-islet cells, was chosen for this study since these animals undergo tumorigenesis in a reproducible series of stages, one of which involves the initiation of angiogenesis (Folkman et al., 1989; Hanahan, 1985) . We first examined the expression of ephrin-A1 and EphA2 protein in the bTC cell line, a pancreatic islet cell carcinoma cell line that was originally derived from RIP-Tag tumors (Radvanyi et al., 1993) and in the MS-1 pancreatic microvascular endothelial cell line (Arbiser et al., 1997) by immunoblot analysis. We detected abundant ephrin-A1 expression in both tumor and endothelial cell lines, though EphA2 expression was restricted to endothelial cells (Figure 1a) .
To verify these expression patterns within intact RIP-Tag tumors in vivo, anti-ephrin-A1 antibodies were used to stain RIP-Tag islet cell carcinoma sections. Ephrin-A1 protein was expressed predominantly within the carcinoma cells (Figure 1b,e) . Expression of ephrin-A1 was also localized within the endothelium of some tumor-associated blood vessels by comparison with adjacent sections stained for CD31, an endothelial cell-specific marker (Figure 1e ,f, arrowhead). Ephrin-A1 expression was not detected in adjacent exocrine tissue (Figure 1b, e, arrows) . In contrast, compared with CD31 expression (Figure 1d , arrowhead), EphA2 protein appeared to be specifically localized in tumor associated vasculature and was not detected in carcinoma cells (Figure 1c, arrowhead) , consistent with the data obtained from immunoblot analysis (Figure 1a) . Localization of ephrin-A1 and EphA2 in tumor endothelial cells was also confirmed by dual immunofluorescence expression analysis using the endothelial cell specific marker CD31 (Figure 1h -m) .
As RIP-Tag tumor angiogenesis is dependent on signaling by vascular endothelial growth factor (VEGF; Bergers et al., 2000) , and as soluble EphA2-Fc receptor can inhibit VEGF-induced angiogenesis in corneal assays (Cheng et al., submitted) , we analysed expression of EphA2 and ephrin-A1 relative to VEGF in adjacent tumor sections (Figure 1n -p) . VEGF and ephrin-A1 were abundantly expressed in islet cell carcinomas in overlapping patterns (Figure 1o,p) . The complementary patterns of ephrin-A1 and EphA2 proteins in tumor cells and associated blood vessels suggest that functions of EphA ligand/receptor may be required to promote tumor neovascularization.
Soluble EphA2-Fc receptor inhibits RIP-Tag tumorinduced angiogenesis
To determine if class A Eph receptor/ligand regulates tumor angiogenesis, we used EphA2-Fc as an inhibitor in an in vivo cutaneous tumor vascular window assay (Figure 2a ). In this assay system, a fold is secured in the dorsal skin of a mouse and a circular portion of skin is removed from one side of the fold. This creates a 'window' that exposes the subcutaneous blood vessels on the inner flap of skin on the opposite side of the fold. This window preserves the exposed opposite surface for observation through a glass coverslip, which is fastened on top of the subcutaneous skin surface. Previous studies have demonstrated that small tumors placed within the dorsal window chamber become vascularized by subcutaneous host blood vessels and undergo rapid growth within 10 -14 days (Huang et al., 1999; Li et al., 2000; Papenfuss et al., 1979) . This system enabled us to monitor the angiogenic response of the subcutaneous host blood vessels initiated by tumor-derived signals in live animals by photomicroscopy.
In order to ascertain the role of Eph A class receptor function in tumor angiogenesis, we utilized a soluble chimeric protein (EphA2-Fc) in which the extracellular domain of the EphA2 receptor is fused to the human IgG1 Fc chain. We have shown that EphA2-Fc prevents the interaction of multiple ephrin A class ligands with endogenous receptors, effectively blocking A class Eph receptor activation in cell culture, and inhibiting corneal angiogenesis in vivo (Cheng et al., submitted) .
As shown in Figure 2 , small islet cell carcinomas were isolated from RIP-Tag mice and placed in the window chamber (outlined in blue). Hydron pellets (outlined in yellow) impregnated with EphA2-Fc, human IgG (Fc control), or PBS were implanted adjacent to islet tumors in window chambers mounted on syngeneic animals (Figure 2a -i) . After 10 -14 days the islet tumors co-implanted with control IgG or PBS pellets elicited a robust angiogenic response . To determine if tumor associated vessels were Figure 1 Ephrin-A1 and EphA2 are expressed in pancreatic islet cell carcinoma and/or associated tumor vasculature. (a) Total cellular protein (60 mg) from the RIP-Tag tumor-derived bTC cell line and from the MS-1 pancreatic microvascular endothelial cell line was subjected to immunoblot analysis for expression of ephrin-A1 and EphA2. Expression of ephrin-A1 was detected in both tumor and endothelial cells, while EphA2 expression was restricted to endothelial cells. (b -g) Adjacent pancreatic sections (10 mm) from tumor-bearing Rip-Tag mice were subjected to immunohistochemistry to detect the expression of ephrin-A1, EphA2, and CD31. Ephrin-A1 is expressed in RIP-Tag islet tumor cells (b,e) and in tumor associated endothelial cells (e, arrowhead), and EphA2 is expressed in blood vessel endothelial cells (c, arrowheads), as compared to an adjacent section stained with CD31 (d, arrowheads). Expression of ephrin-A1 was not observed in adjacent exocrine tissue (b,e, arrows) . (h -m) Expression of ephrin-A1 and EphA2 relative to CD31 endothelial cell marker was assessed by dual immunofluorescence analysis. (h) Ephrin-A1 expression (red) was predominantly in tumor cells surrounding (i) CD31 (green) expressing endothelial cells, although there was some co-localization within endothelial cells (j, merged image, arrows). (k) EphA2 expression (red) co-localized with (l) CD31 expression (green) in endothelial cells (m, merged image, arrowheads). (n -p) Ephrin-A1 expression in RIP-Tag islet cell tumors co-localizes with VEGF expression in 5 mm adjacent sections. n=3 to 6 independent samples. Scale bars: (b) and (n), 100 mm, (e), (h) and (k), 50 mm functional and to visualize microvessels associated with the tumor, FITC-conjugated dextran was given intravenously. The vessels associated with RIP-Tag tumors adjacent to PBS and IgG-impregnated pellets were perfused well, as they were efficiently labeled with fluorescent dextran (Figure 2c,d ) and blood flow was visualized under the digital camera. In contrast, no visible, functional blood vessels were observed in islet tumors adjacent to EphA2-Fc pellets (Figure 2f -i) . Vessel density within the tumor was quantified using Scion Image (Figure 2j) . A 28-fold decrease in blood vessel density within the tumor was observed in 
EphA2-Fc-treated mice versus controls (P50.01). To verify that this effect was specific for EphA2-Fc protein and not potential co-purified contaminants, two batches of independently purified soluble receptors were tested. Both batches efficiently blocked tumor angiogenesis compared to control proteins. These data suggest a requirement for EphA receptor/ligand function in tumor angiogenesis.
Ephrin-A1 and EphA2 are expressed in 4T1 tumors and associated vasculature
To determine whether our observations are relevant for other tumor types, we investigated the role of class A Eph receptors and ligands in tumor angiogenesis in 4T1 mammary adenocarcinoma. We selected the 4T1 model due to the ability of transplanted 4T1 cells to rapidly and reproducibly generate mammary adenocarcinoma in syngeneic animals in vivo (Aslakson and Miller, 1992; Lin et al., 1998) . Expression of ephrin-A1 and EphA2 in EMT6 cells was also analysed, as these tumor cells also produce malignant adenocarcinomas in vivo, though with a slower progression than 4T1 cells (Rockwell, 1977 (Rockwell, , 1978 (Rockwell, , 1981 . As shown in Figure 3a , ephrin-A1 was barely detectable in normal primary mouse mammary epithelial cell (PMEC) lysates, but was expressed at high levels in 4T1 and EMT6 tumor cells. EphA2 overexpression was observed in 4T1 and EMT6 tumor cell lysates relative to cultured PMECs. Overexpression of both ephrin-A1 and EphA2 was also detected in 4T1-GFP cells, a 4T1 subline expressing green fluorescent protein (Li et al., 2000) , used in subsequent functional analyses.
Next, we examined expression and localization of ephrin-A1 and EphA2 proteins in tissue sections from 4T1 tumors produced by injection of 4T1 cells into the mammary gland fat pad of female syngeneic Balb/c mice. In 4T1 tumor sections, ephrin-A1 was detected in tumor cells throughout the course of tumor progression from 3 to 9 days post-transplantation (Figure 3b i, arrowheads indicate tumor blood vessels). Expression of ephrin-A1 appeared to increase steadily from day 3 to day 9 (Figure 3b -d) . Although EphA2 expression was detected in tumor cells at lower levels (Figure 3h) , it was predominantly expressed in tumor-associated peripheral blood vessels and in internal microvessels 6 days after injection of 4T1 cells (Figure 3f ,i, arrowheads), and expression persisted up to 9 days postinjection (Figure 3g, arrowhead) . Co-localization of ephrin-A1/EphA2 expression with endothelial cells was confirmed by dual immunofluorescent staining with CD31 (Figure 3j -r) .
As our previous studies indicate that VEGFmediated angiogenesis can be inhibited by soluble EphA2-Fc receptor (Cheng et al., submitted) , and as blocking VEGF signaling abrogates tumor 4T1 tumor angiogenesis (Li et al., 2000; Prewett et al., 1999) , we examined the expression patterns of ephrin-A1 and EphA2 relative to VEGF and activated VEGF receptor in adjacent 4T1 tumor sections (Figure 3s -x) . Colocalization of ephrin-A1 and VEGF protein expression was detected in tumor cells surrounding blood vessels (Figure 3s ,t, arrowheads indicate location of tumor blood vessels). We compared the expression of EphA2 with activated VEGF receptor (VEGF : R) using an antibody that specifically recognizes VEGF in complex with VEGFR-1 or VEGFR-2 (Bergers et al., 2000; Brekken et al., 1998) . EphA2 expression colocalized with activated VEGF : R in tumor microvessels, as demonstrated by comparison of immunostaining in 5 mm adjacent sections ( Figure  3v ,w, arrowheads indicate location of tumor blood vessels). These overlapping expression patterns of ephrin-A1 and VEGF ligands, as well as EphA2 and activated VEGF receptors, suggest that class A Eph ligand/receptor may also function in concert with VEGF to regulate 4T1-induced tumor angiogenesis.
Soluble EphA2-Fc inhibits 4T1 tumor cell-induced angiogenesis
We examined the function of A class Eph receptors/ ligands in 4T1 tumor cell-mediated blood vessel recruitment and tumor progression by using EphA2-Fc in the cutaneous tumor vascular window assay. 4T1 cells have been shown to elicit a robust angiogenic response in this assay system (Huang et al., 1999; Li et al., 2000) . Hydron pellets (outlined in yellow) impregnated with PBS vehicle, control human IgG, or EphA2-Fc were co-implanted into the dorsal skin fold of mice along with 4T1-GFP cells (green). The stable expression of GFP within this 4T1 subline provides a means of tracking tumor cells in the window chamber (Li et al., 2000) . After 10 -14 days, rhodamine-conjugated dextran was given intravenously to visualize host blood vessel perfusion and small microvessels by fluorescence microscopy. Abundant new vessel growth was detected adjacent to 4T1 tumor cells in control windows ( . (e -g) EphA2 expression was detected as early at 6 days post-injection within peripheral tumor blood vessels (arrowheads), and expression persisted up to 9 days. (h and i) EphA2 expression was also detected within tumor cells (h) and in microvessels within the tumor (i, arrowheads) at 6 days post-injection. (j -r) Cryosections (7 mm) from 6 day 4T1 tumors were subjected to dual immunofluorescence analysis for expression of ephrin-A1 or EphA2 and the endothelial specific marker CD31. Ephrin-A1 (j) protein expression (red) was predominantly expressed in tumor cells, though some co-localization with CD31 (k) protein expression (green) in associated tumor blood vessels was detected (l, yellow in merged image, arrowheads). EphA2 (m) protein expression (red) localized to tumor cells, and also co-localized with CD31 (n) protein expression (green) in associated tumor blood vessels in the same section (o, yellow in merged image, arrowheads). (p -r) Staining for ephrin-A1, EphA2, and CD31 was specific, as fluorescence conjugated secondary antibodies displayed minimal background. (s -x) Adjacent sections (5 mm) from 4T1 tumors 6 days post-injection were probed for expression of ephrin-A1, VEGF, EphA2, and activated VEGF receptor (VEGF : R) in complex with VEGF. Ephrin-A1 expression (s) colocalized with VEGF (t) expression in tumor cells surrounding blood vessels (arrowheads), and EphA2 expression (v) co-localized with activated VEGF receptor (w). Specificity of staining was confirmed by probing adjacent sections with control rabbit IgG (u, rIgG) or mouse IgG (x, mIgG). Arrowheads indicate blood vessels (n=3 independent samples per condition). Scale bars: b and s, 100 mm; h, 50 mm; i, j, and v, 5 mm mixture was injected into female mice subcutaneously. The mice were treated daily with 10 mg soluble factors by subcutaneous injection at the site of the tumor for 14 days, and tumors were then ressected for analysis. Treatment with EphA2-Fc or EphA3-Fc resulted in a threefold reduction in tumor volume relative to 4T1 tumors treated with IgG (P50.05; Figure 5i ). Furthermore, 4T1 cells elicited a robust angiogenic response in Matrigel plugs, whereas Matrigel by itself did not induce any angiogenic response (Figure 5a versus d). Consistent with data derived from the window assays, treatment with EphA2-Fc resulted in a marked reduction in both surface vascular density (Figure 5a versus b, arrowheads indicate blood vessels) and in microvessel density within the tumor, as determined by CD31 staining (Figure 5e versus f, arrowheads indicate microvessels). We observed a 2.5-fold decrease in microvascular density in EphA2-Fctreated 4T1 tumors versus IgG-treated controls, as quantified by CD31 fluorescence intensity (P50.05, Figure 5h ). Treatment of Matrigel plugs with EphA2-Fc resulted in significantly reduced tyrosine phosphorylation of endogenous EphA2 relative to IgG, suggesting that these soluble receptors disrupt EphA2 signaling in vivo (Figure 5j ). Taken together, these data suggest that class A Eph ligands and receptors are required in 4T1 tumor angiogenesis and progression in vivo. The decrease in vascular density and tumor volume in EphA2-Fc/EphA3-Fc treated 4T1 Matrigel plugs may be due to direct inhibition of tumor angiogenesis. Alternatively, EphA-Fc may affect tumor cell growth and/or induce tumor cell death thereby indirectly inhibiting tumor angiogenesis. To determine if the inhibitory effect of soluble EphA receptor was specific to tumor angiogenesis, rather than growth or survival of tumor tissue, we compared levels of cell growth and cell death in 4T1 tumors with that of cultured 4T1 cells in vitro. 4T1 cell growth in vivo was assessed by quantifying expression of proliferating cell nuclear antigen (PCNA), a marker for actively dividing cells, including breast carcinoma cells (Aaltomaa et al., 1993; Preziosi et al., 1995) . Tumors treated with EphA2-Fc or EphA3-Fc displayed a 2.2-fold reduction in PCNA expression relative to control IgG-treated tumors (Figure 6b versus a, arrowheads indicate PCNA positive nuclei; data for EphA3-Fc not shown), as determined by quantification of PCNA positive nuclei relative to total nuclei/field (P50.01; Figure 6c ). In contrast, treatment with EphA2-Fc did not affect serum-induced 4T1 cell growth (Figure 6d) , suggesting that blocking EphA-Fc does not directly affect tumor cell proliferation.
We also compared levels of 4T1 cell apoptosis in Matrigel plugs versus 4T1 cells cultured in the presence or absence of EphA2-Fc or EphA3-Fc by TUNEL assay. 4T1 tumors treated with EphA2-Fc or EphA3-Fc displayed a 3.2-fold increase in TUNEL positive nuclei; data for EphA3-Fc not shown), as determined by quantification of TUNEL positive nuclei relative to control IgG-treated tumors (Figure 6f versus e, arrowheads indicate TUNEL positive nuclei relative to total nuclei/field (P50.05, Figure 6g ). We then measured apoptosis in 4T1 cells cultured in serum-free media as a positive control for the induction of apoptosis in these cells, or in full-serum media in the presence or absence To determine how EphA2-Fc affects endothelial cell function, we investigated the effect of EphA2-Fc on endothelial cell proliferation, apoptosis, and migration. Consistent with previous studies (reviewed by Gale and Yancopoulos, 1999 ; blocking EphA receptor activation did not affect endothelial cell proliferation (data not shown). Ephrin A-1 ligand has been shown to regulate endothelial cell migration (Daniel et al., 1996; Pandey et al., 1995) , suggesting that overexpression of ephrin-A1 in tumor tissue could promote migration and infiltration of endothelial cells in tumor tissue. To test this, we first examined migration of microvascular endothelial cells in response to soluble ephrin-A1 in a modified Boyden chamber assay. Ephrin-A1 induced migration of bovine pulmonary microvascular endothelial cells (BPMECs), consistent with previous studies performed using other endothelial cell types (Daniel et al., 1996; Pandey et al., 1995) . Excess EphA2-Fc inhibited ephrin-A1 induced endothelial cell migration (P50.01, Figure 7a ), and the inhibition was specific, as excess Fc control protein, IgG, did not inhibit ephrin-A1-induced migration. Soluble EphA2-Fc alone did not influence endothelial cell migration (data not shown; Cheng et al., submitted). Since our previous studies indicate that VEGF-mediated angiogenesis can be inhibited by soluble EphA2-Fc (Cheng et al., submitted) , and as blocking VEGF signaling abrogates RIP-Tag and 4T1 tumor angiogenesis (Li et al., 2000; Prewett et al., 1999) , we also tested the ability of EphA2-Fc to inhibit VEGF induced endothelial cell migration. VEGF-induced BPMEC migration was inhibited by EphA2-Fc (P50.01, Figure  7a ), suggesting that VEGF and ephrin signaling pathways cooperate to mediate endothelial cell migration.
We next assessed BPMEC migration in response to tumor cells in Boyden chamber co-culture assays (Laferriere et al., 2001 ). 4T1 and bTC cells were plated on the lower surface of Boyden chambers and labeled with FITC (Figure 7b -f ). BPMECs were labeled with Texas-red and added to the upper chamber, and migration and intercalation of endothelial cells was quantified by fluorescence intensity (Figure 7g -k) . Both bTC and 4T1 cells stimulated migration of BPMECs (Figure 7g ,j, arrowheads indicate endothelial cells; Figure 7l ,m). The induction of migration appeared to be specific to tumor cells, as non-malignant NMuMg (Owens et al., 1974; Van den Broecke et al., 1996) cells did not induce BPMEC migration (Figure 7i,m) . Addition of EphA2-Fc inhibited migration of BPMECs in response to both 4T1 and bTC (P50.01, Figure 7k ,h,l,m), demonstrating that Eph A class receptor/ligand function is necessary for endothelial cell migration in response to tumor cells. These data suggest that EphA2-Fc specifically affects the angiogenic response initiated by tumors at the level of endothelial cell migration, providing further support for a pro-angiogenic role for Eph A class receptors in tumor progression.
Discussion
The functions of Eph receptor tyrosine kinases and their ligands during embryonic development have been intensively studied. In addition to critical roles in axon guidance and tissue boundary formation, certain Eph receptors and their ligands are also required for vascular development during embryogenesis. However, the role of the Eph family in neovascularization during pathologic states in adults remains unclear. In this study, we provide the first functional data showing that class A Eph RTKs and ephrins play a critical role in tumor angiogenesis. Ephrin-A1 ligand is expressed predominantly in tumor cells, and EphA2 receptors are expressed primarily in a complementary fashion in the tumor-associated vasculature. Furthermore, treatment with soluble EphA2-Fc chimeric receptor results in decreased neovascularization in two different tumor types in vascular window assays, and EphA2-Fc or EphA3-Fc treatment results in decreased tumor vascular density and impaired tumor progression in vivo. These data indicate that EphA signaling is a critical component for tumor progression, and that regulation of tumor neovascularization may play a significant role in EphA mediated tumor progression.
Our expression data demonstrated that ephrin-A1 is elevated in RIP-Tag islet cell carcinoma and in 4T1 mammary adenocarcinoma, and to a certain extent, is also expressed in tumor associated vessels. In contrast, EphA2 receptor is expressed in both endothelial cells and in tumor cells, depending on tumor type. Specificity of immunoreaction was confirmed by probing adjacent sections with normal mouse IgG (Figure 1g ) or rabbit IgG. Moreover, anti-ephrin-A1 antisera specificity was confirmed using two different antibodies and competition experiments using purified ephrin-A1 protein (data not shown). The EphA2 antibody has been used previously to detect expression in tumor tissue (Walker-Daniels et al., 1999), and specificity was confirmed by immunoblot (data not shown). A number of studies reported overexpression of EphA2 receptor and/or ephrin-A1 in tumors, but in most cases the cellular distribution in vivo has not been characterized (Easty et al., 1995 (Easty et al., , 1999 WalkerDaniels et al., 1999; Zantek et al., 1999) . Consistent with our observations, more recent studies report that expression of ephrin-A1 and EphA2 co-localized with tumor tissue and/or associated tumor vasculature in human tumor xenografts and biopsies from primary tumors (Ogawa et al., 2000; Zelinski et al., 2001) . Taken together, these studies and our findings suggest that the functional data presented in this study may represent a broad mechanism by which EphA class receptor/ligand regulates tumor progression.
Elucidation of the in vivo functions of Eph ligands and receptors in adult angiogenesis is complicated by functional redundancy within the Eph family and embryonic lethality resulting from targeted disruption of some individual Eph family members (Adams et al., 1999b; Chen and Ruley, 1998; Gerety et al., 1999; Wang et al., 1998a) . To circumvent these difficulties, we have utilized a soluble chimeric receptor fusion protein, EphA2-Fc, in which the extracellular ligandbinding domain of the EphA2 receptor is fused to the Fc portion of human IgG1. This soluble receptor effectively blocks endogenous receptor phosphorylation by competitively binding available ligand and inhibits ephrin-A1-induced corneal angiogenesis in vivo (Cheng et al., submitted). The inhibitory effects of soluble EphA2-Fc is specific to class A Eph receptor activation, as EphA2-Fc has no effect on B class Eph receptor activation or phosphorylation of VEGF receptor (data not shown). The use of Fc chimeric fusion proteins, however, raise the possibility that the binding of EphA2-Fc or EphA3-Fc to membrane tethered ephrin-A1 ligand may initiate an immune response leading to complement and/or cell-mediated cytotoxicity and clearance of tumor cells and/or endothelial cells. We do not favor this hypothesis as the EphA3-Fc fusion protein, which contains mutations in the Fc region that inhibit interaction with complement and Fc receptor, produces effects comparable to EphA2-Fc on vascular density and tumor progression in vivo.
What is the mechanism of EphA-Fc-mediated inhibition of tumor progression in vivo? In principle, inhibition of tumor growth/survival in vivo could be achieved through direct inhibition of proliferation and survival of tumor cells, as 4T1 tumor cells express EphA2 receptor. Alternatively, blocking EphA receptor activation could indirectly affect tumor cell growth and viability via regulation of blood vessel recruitment. To distinguish between these two possibilities, we compared tumor cell proliferation and apoptosis both within the intact tumor and in cell culture. Our data demonstrate that EphA-Fc does not affect tumor cell proliferation and survival in culture, though a decrease in tumor cell proliferation and an increase in tumor cell death was observed in tumor-bearing animals treated with EphA2-Fc or EphA3-Fc. Treatment of EphA-Fcs in tumor-bearing animals did result in a significant reduction in tumor vascular density in intact tumors in vivo, consistent with the reduction in vascular density observed in cutaneous window assays. In addition, blocking soluble EphA-Fc receptor also inhibited endothelial cell migration in response to tumor cells in transwell co-culture assays. Taken together, these data suggest that soluble EphA-Fc receptor modulate tumor progression by inhibiting tumor angiogenesis, which deprives the tumors of blood-borne oxygen, nutrients, and growth/survival factors. These data are consistent with known functions of Eph receptors and ligands, including ephrin-A1, in mediating endothelial cell migration and assembly (Daniel et al., 1996) , as well as the ability of a truncated, dominant negative EphA2 receptor mutant to inhibit endothelial cell assembly into capillary-like structures in vitro (Ogawa et al., 2000) .
One unique feature of the Eph family is that their ligands are membrane-bound (Holder and Klein, 1999) . It is therefore intriguing to hypothesize how ephrin-A1 expressed on tumor cells could stimulate an angiogenic response from vessels that are not in direct contact with the tumor. One possibility is that ephrin-A1 ligand may be cleaved from the surface of tumor cells, and that soluble ephrin-A1 may then act as a long-range signal to activate EphA2 receptor on local endothelial cells to initiate angiogenesis. Indeed, ephrin-A1 was originally characterized as a secreted protein, detected in conditioned media from HUVECs after stimulation with TNF-a (Holzman et al., 1990) . In addition, cleavage of cell surface ephrin-A2 to a soluble form by Kuzbanian metalloprotease has been reported in the developing central nervous system during embryogenesis (Hattori et al., 2000) . We do not currently favor this hypothesis as a possible mechanism of ephrin-A1 mediated angiogenesis in our tumor models, however, since soluble ephrins have not been found to be biologically active in the absence of artificial clustering (Davis et al., 1994; Gale and Yancopoulos, 1997) . Furthermore, we have not detected soluble ephrins in culture media from RIP-Tag-derived bTC cells or from 4T1 cells (data not shown).
Based on the expression patterns of ephrin-A1 ligand and EphA2 receptor in tumors and on the ability of EphA2-Fc to inhibit many of the angiogenic activities of VEGF, we propose a cooperative model of ephrinA/ EphA-mediated tumor angiogenesis in the context of the VEGF-pathway. In such a model, ephrin-A1 could function to induce tumor angiogenesis through both paracrine and juxtacrine mechanisms. As shown in Figure 1p , and Figure 3t , both RIP-Tag and 4T1 tumors express high levels of VEGF. Thus, when tumor cells and endothelial cells are not in direct contact, VEGF expressed by tumors could induce ephrin-A1 expression in adjacent endothelial cells (Cheng et al., submitted) , as suggested by co-localization of ephrin-A1 with CD31 (Figure 1) . Engagement of ephrin-A1 to EphA2 receptor may then activate juxtacrine signaling to regulate changes in endothelial cell morphology, cell -cell, and cell -matrix contact to promote angiogenesis. This hypothesis is in consistent with VEGF expression in the tumors (Figures 1 and 3) and that VEGF-induced endothelial cell migration can be blocked by soluble EphA2-Fc receptor (Figure 7a ). Once endothelial cells are in direct contact with tumor cells in vivo, tumor cells may direct new blood vessel growth through paracrine signaling between ephrin-A1 expressed on tumor cells and EphA2 expressed on surrounding endothelial cells. This is supported by our tumor cell-endothelial cell co-culture data. As shown in Figure 7b -m, in a transwell assay that stimulates tumor-endothelium interaction in vitro, endothelial cells migrate towards malignant bTC or 4T1 tumor cells, but not non-malignant NMuMg cells, and this migration was blocked by EphA2-Fc. Thus, VEGF provides a relatively long-range signal while ephrin-A1 provide a contact signal, both of which act in concert to regulate tumor angiogenesis.
Given recent reports of reverse signaling through ephrin ligands upon stimulation with Eph receptors, it is also possible that EphA2-Fc or EphA3-Fc could initiate ephrin-mediated reverse signaling in ephrin-A1 expressing tumor cells and/or endothelial cells. Indeed, stimulation of ephrin-A2 and ephrin-A5 expressing cells with soluble EphA receptors results increased cellular adhesion involving downstream signaling targets such as b1 integrin and src/fyn intracellular tyrosine kinases (Davy et al., 1999; Davy and Robbins, 2000; Huai and Drescher, 2001 ). Thus, activation or modulation of signaling cascades downstream of ephrins expressed on the surface of tumor and/or endothelial cells by soluble EphA receptors might therefore initiate changes in adhesion and migration that could contribute to decreased angiogenesis observed in the window assays and in Matrigel plugs. We do not currently favor this hypothesis, however, as EphA2-Fc stimulation alone does not induce angiogenesis in mouse corneal assays (Cheng et al., submitted) , nor does EphA2-Fc treatment alone alter endothelial cell migration, sprouting, proliferation, or apoptosis (data not shown). Moreover, reduced expression of EphA2 receptor in endothelial cells by transfection of antisense oligonucleotides mimics the inhibitory effects of soluble receptor on endothelial cell migration, favoring the interpretation of disrupted EphA class receptor function by soluble receptors (Cheng et al., submitted) . Though we cannot rule out modulation of ephrin-A signaling by treatment with soluble Eph receptors, we have shown that EphA2-Fc treatment blocks tyrosine phosphorylation of endogenous EphA2 receptor in endothelial cells stimulated with soluble ephrin-A1, as well as corneal angiogenesis induced by soluble ephrin-A1 (Cheng et al., submitted) . Moreover, EphA2-Fc treatment reduces endogenous EphA2 receptor phosphorylation in 4T1 Matrigel plugs relative to controls, (Figure 5j ) supporting the inhibitory function of soluble EphA receptors on EphA class signaling.
In summary, we provide the first evidence that engagement of class A Eph receptors and ligands regulate tumor angiogenesis. In addition, treatment of tumor-bearing mice with soluble EphA class receptors results in reduced tumor volume and vascular density without directly affecting proliferation or apoptosis, suggesting that these molecules may modulate angiogenesis-dependent tumor progression. Thus, A class Eph receptors and ligands may be effective new therapeutic targets for cancer treatment.
Materials and methods
Soluble EphA-Fc receptors
The EphA2-Fc soluble receptor cDNA construct was provided by Regeneron Inc. (Tarrytown, NY, USA) and subcloned into episomal expression vector pCEP4 (Invitrogen, San Diego, CA, USA). pCEP4/ephrin-A1-Fc expression vector was provided by Dr A Pandy (University of Michigan, Ann Arbor, MI, USA). Recombinant EphA2-Fc and ephrin-A1-Fc proteins were either purified from culture supernatant of stable 293T clones expressing these factors using protein A sepharose column, or purchased from R&D Systems (Minneapolis, MN, USA). Recombinant EphA3-Fc protein was provided by Immunex Inc. (Seattle, WA, USA). The Fc region in EphA3-Fc was mutated to inhibit binding to Fc receptors and complement.
Mouse strains and maintenance RIP1-Tag2 C57B1/6 mice (generously provided by Doug Hanahan, University of California at San Francisco) and wild-type C57BL/6 and Balb/c mice were maintained in accordance with AAALAC and Vanderbilt University guidelines. RIP1-Tag2 transgenic animals (Folkman et al., 1989; Hanahan, 1985) were maintained on a sucrose-enriched diet (Teklad Test Diets, Madison, WI, USA) and 4% glucose water. Animals positive for the RIP-Tag transgene were identified by PCR analysis of genomic DNA from tail biopsy using the following primers: 5'-GGACAAACCACAACTA-GAATG-3' and 5'-CAGAGCAGAATTGTGGAGTGG-3'. (Aslakson and Miller, 1992; Lin et al., 1998) and 4T1-GFP (a generous gift from Chuan-Huan Li, Duke University, (Li et al., 2000) ) cell lines were maintained in DMEM with 10% fetal calf serum. For transplantation experiments, 2610 5 cells in 0.1 ml media were injected into the number four inguinal mammary fat pad of 10 -15-week-old syngeneic Balb/c female mice using a 1 ml syringe and a 30 gauge needle. Tumors derived from these injected cells were surgically collected from the mice 3, 6, and 9 days postimplantation.
4T1 cell culture and transplantation
4T1
For tumor progression studies, 1610 5 4T1 cells were suspended in 300 ml of liquid growth factor reduced Matrigel (Becton-Dickinson, Franklin Lakes, NJ, USA) in the presence or absence of 10 mg EphA2-Fc (R&D Systems, Minneapolis, MN, USA), EphA3-Fc (Immunex Corporation), or human IgG (Sigma-Aldrich Corporation, St. Louis, MO, USA). The suspension was injected subcutaneously on the dorsal flank of 10-to 15-week-old syngeneic Balb/c female mice using a 1 ml syringe and a 30 gauge needle (Passaniti et al., 1992) . The mice were injected daily with 10 mg EphA2-Fc, EphA3-Fc or IgG in 100 ml of PBS subcutaneously at the site of Matrigel plug implantation. The plugs were collected and the length and width of each tumor was measured using a caliper. Tumor volume was calculated by the following formula: Tumor volume=0.526 width 2 6length (Bergers et al., 1999) . Data are a representation of five to 10 independent samples per condition, and statistical significance was assessed by twotailed, paired Student's t-test.
Immunoblot and immunoprecipitation analyses bTC pancreatic carcinoma (Radvanyi et al., 1993) , 4T1, and EMT6 (Rockwell, 1977 (Rockwell, , 1978 (Rockwell, , 1981 mouse mammary adenocarcinoma cell lines were maintained in DMEM with 10% FCS. Primary mouse mammary epithelial cells were isolated and maintained as described previously Muraoka et al., 2001 ). An MS-1 endothelial cell line was maintained in endothelial cell growth (EGM) media from Clonetics (Cambrex Corporation, East Rutherford, NJ, USA). Total cellular proteins from these cells were isolated by lysis in ice-cold RIPA buffer supplemented with protease inhibitors [PMSF (100 mg/ml), aprotinin (40 mg/ml), and leupeptin (2 mg/ml)]. Sixty mg of protein lysate from bTC and MS-1 cells, or 40 mg protein lysate from 4T1, EMT6, and PMECs, were fractionated on 8 -10% SDS-polyacrylamide gels. The proteins were then transferred to nitrocellulose membranes and probed with anti-EphA2 antibodies (Upstate Biotechnology, Lake Placid, NY, USA; 1 mg/ml) and antiephrin-A1 antibodies (Immunex, Seattle, WA, USA; 1 : 500). Specific immunoreaction was detected using anti-IgG antibodies conjugated to horseradish peroxidase (Promega, Madison, WI, USA) and ECL plus chemiluminescence detection kit (Amersham Pharmacia Biotechnology). The blots were stripped and re-probed with anti-b-tubulin (Sigma-Aldrich, 1 : 750) antibodies to confirm uniform loading. Data are a representation of five independent samples per cell line.
For immunoprecipitation of EphA2 from Matrigel plugs, tumor plugs were collected, frozen on dry ice and pulverized by mortar and pestle. Lysates were prepared as described above (RIPA buffer supplemented with 1 mM sodium orthovanadate phosphatase inhibitor (Sigma-Aldrich)), and EphA2 was immunoprecipitated from 500 mg lysate using anti-EphA2 antibodies (Santa Cruz Biotechnology; Upstate Biotechnology) plus A/G-sepharose beads (Santa Cruz Biotechnology). Products were fractionated as above and blots probed with anti-phosphotyrosine antibodies pY99 and pY20 (Santa Cruz Biotechnology). Blots were stripped and re-probed with anti-EphA2 antibodies (Upstate Biotechnology).
Histological analyses
RIP-Tag pancreatic tumors (isolated from 11-week-old mice) and 4T1-derived tumors were isolated and fixed in 10% neutral buffered formalin overnight at 48C. The tissue was then paraffin-embedded and 7 -10 mm sections prepared. Alternatively, the tissue was fixed in 4% paraformaldehyde in PBS for 1 h, equilibrated into 30% sucrose in PBS overnight, and embedded in O.C.T. for preparation of cryosections. Immunohistochemical detection was performed as described previously (Brantley et al., 2000 , using primary antibodies against ephrin-A1 (Immunex, 1 : 200), EphA2 (Upstate Biotechnology, 10 mg/ml), VEGF (Neomarkers, Freemont, CA, USA; 10 mg/ml), and activated VEGF receptor (GV39M, 1 : 500; Bergers et al., 2000; Brekken et al., 1998) ). Sections were counterstained with Mayer's hematoxylin, mounted, and photographed using an Olympus BX60 microscope.
For dual immunofluorescence analysis, cryosections (7 mm) were probed with primary antibodies for CD31 (BD Pharmingen, San Diego, CA, USA) and ephrin-A1 or EphA2, followed by secondary antibodies conjugated to Alexa 488 green fluorochrome (anti-rat IgG, 1 : 2000; Molecular Probes, Eugene, OR, USA) for CD31 staining or Cy3 red fluorochrome (anti-rabbit IgG-Cy3, 1 : 2000; Jackson Immunoresearch Laboratories, West Grove, PA, USA; antimouse IgG-Cy3, Molecular Probes) for ephrin-A1 and EphA2 staining, respectively. Sections probed with mouse anti-EphA2 antibodies were treated with mouse-on-mouse (M.O.M.) blocking reagents to reduce background staining from endogenous mouse IgGs (Vector Laboratories, Burlingame, CA, USA). Sections were counterstained with DAPI (Sigma-Aldrich) to visualize nuclei. Fluorescence images were captured using an Olympus BX60 microscope and digital camera. Digital images were processed and merged using Adobe Photoshop 5.5 software. Data are representations of three to six independent samples per condition for immunohistochemical analyses.
Cutaneous window assays
Window assays were performed as described previously (Huang et al., 1999; Li et al., 2000) . Briefly, a 5 mm diameter flap of skin was dissected away from the dorsal skin flap of anesthetized recipient mice (C57B1/6 recipient mice for RIPTag and Balb/c mice for 4T1 cells), leaving a fascial plane with associated vasculature. A hydron pellet impregnated with normal human IgG (Sigma-Aldrich, 1 mg/pellet), EphA2-Fc (1 mg/pellet, purified in house or from R&D Systems), or PBS was implanted in the window chamber adjacent to a RIP-Tag tumor (approximately 0.7 mm in diameter) isolated from eleven-week-old transgenic mice. In addition, window assays were performed using cultured 4T1-GFP cells (approximately 1000 cells) under the same conditions. The chambers were sealed with glass coverslips. Ten to 14 days after implantation, fluorochrome-conjugated dextran (2% in PBS, Sigma-Aldrich: FITC-conjugated dextran, 40 kDa, for RIP-Tag windows and rhodamine conjugated dextran, 65 kDa, for 4T1-GFP windows) was injected intravenously, and tumors in window chambers were photodocumented using an Olympus BX60 microscope and digital camera.
Density of blood vessels within the window chambers was quantified by fluorescence intensity of FITC or rhodaminedextran using Scion Image software. The density of fluorescent pixels within each 106tumor field was determined and compared in control IgG or PBS treated windows versus EphA2-Fc treated windows, and statistical significance was determined by two-tailed, paired Student's t-test. Density of 4T1GFP cells was also quantified by fluorescence intensity using Scion Image software (version 1.62c). The density of fluorescent pixels 7 days post-implantation relative to the total pixels within each 26image was calculated, and normalized for initial cell density at 3 days post-implantation. Data are a representation of 6 -8 independent samples per condition with standard error of the mean, and statistical significance was assessed by two-tailed, paired Student's t-test.
Proliferation and apoptosis assays
For cell culture proliferation assays, 1610 5 bTC or 4T1 cells were seeded on 48-well plates and serum-starved for 24 h. The cells were then stimulated with media supplemented with 2% serum, 10% serum, 10% serum plus EphA2-Fc (10 mg/ ml), or 10% serum plus EGF (20 ng/ml) for 3 days. The cells were fixed in 2% glutaraldehyde in PBS, stained with 0.5% crystal violet (Sigma-Aldrich) in 0.2 M boric acid, and washed extensively with deionized water. The stained cells were lysed in 1% SDS and the absorbance of the lysate at 570 nm determined. Proliferation of 4T1 tumor cells in vivo was quantified by PCNA immunohistochemistry. Tumor sections from 4T1 Matrigel plugs (10 mm) were probed with an anti-PCNA antibody (Neomarkers, 1 : 150) as described above, and the percentage of PCNA positive nuclei relative to total nuclei in four random 406tumor fields per sample was calculated. Data are a representation of three to five independent experiments/condition with standard deviation, and statistical significance was assessed by two-tailed paired Student's t-test.
For TUNEL assays 2610 5 bTC or 4T1 cells were seeded on chamber slides (Nalgene-Nunc, Rochester, NY, USA) coated with collagen (Cohesion, Palo Alto, CA, USA). The cells were then cultured in serum-free media, media supplemented with 10% serum, or 10% serum plus EphA2-Fc for 48 h. TUNEL assays were performed using an Apoptag red in situ apoptosis detection kit (Intergen Company, Purchase, NY, USA) according to the manufacturer's protocol. TUNEL staining was quantified by calculating the number of fluorescent pixels in the rhodamine field (TUNEL positive nuclei) and normalizing based on fluorescent pixels within the DAPI field (total nuclei) using Scion Image software. Apoptosis in 4T1 tumor cells in vivo was also quantified. Tissue sections from 4T1 Matrigel tumors (10 mm) were also subjected to TUNEL analysis as described above. Data are a representation of three to five independent experiments/condition with standard deviation, and statistical significance was assessed by two-tailed, paired Student's t-test.
Endothelial cell migration and co-culture assays Endothelial cell migration was assessed using a modified Boyden chamber assay as described previously (Cheng et al., submitted) . Bovine pulmonary microvascular endothelial cells (Clonetics, passage 3 -8) were labeled for 1 h with Texas-red ovalubumin (Molecular Probes; 0.5 mg/ml in DMEM) and detached from tissue culture plates using 0.5 M EDTA. Cells (1610 5 ) were added to upper transwell chambers and the chambers were placed in 24-well dishes supplemented with DMEM/2% FCS (unstimulated) plus ephrin-A1-Fc (R&D Systems, 2.5 mg/ml)+EphA2-Fc (12.5 mg/ml) or human IgG (Sigma-Aldrich, 12.5 mg/ml), VEGF (R&D Systems, 20 ng/ ml)+EphA2-Fc (5 mg/ml). After 5 h, cells were removed from the upper surface of the transwell filter using a cotton swab, and endothelial cell density on the lower surface of the filter was quantified by counting fluorescent pixels using Scion Image software analysis. Data are a representation of nine independent samples per condition with standard deviation, and statistical significance was assessed by twotailed, paired Student's t-test.
For co-culture experiments, transwells were coated with growth factor-reduced Matrigel (1 : 20 dilution in DMEM) and 2610 5 4T1, bTC, or NMuMg (Owens et al., 1974; Van den Broecke et al., 1996) were plated on the lower surface of the transwell filter. Tumor cells on the lower filter surface were labeled with FITC ovalbumin (Molecular Probes; 0.5 mg/ml in DMEM). BPMECs labeled with Texas-red ovalbumin were added to upper transwell chambers as before in DMEM/2% FCS+EphA2-Fc (R&D Systems, 10 mg/ml) or hIgG (R&D Systems, 10 mg/ml). After 5 h, cells were removed from the upper surface of the transwell filter using a cotton swab, and endothelial cell density on the lower surface of the filter was quantified by counting red fluorescent pixels using Scion Image software analysis. Data are a representation of six to nine independent samples per condition with standard deviation, and statistical significance was assessed by two-tailed, paired Student's t-test.
